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Brexpiprazole is a new atypical antipsychotic used for the management of psychiatric conditions 
including schizophrenia and is associated with fewer extrapyramidal side effects compared to 
traditional antipsychotics due to its additional serotonergic effect, which may improve cognitive 
symptoms associated with social function decline in schizophrenia. We searched for randomized 
controlled-trials (RCT) to review the efficacy and tolerability of brexpiprazole in acute management 
of schizophrenia using different resources including PubMed, Google Scholar, ClinicalTrials.gov and 
Cochrane Central Register of Controlled-Trials. Data were extracted for adverse effects, positive and 
negative syndrome scale (PANSS), Personal and Social Performance scale (PSP), PANSS Excited 
Component (PEC) and Response Rate >30%.  5 RCT were identified and showed that brexpiprazole 
was favorable compared to placebo in improving PANSS with a mean difference (MD) -5.40 
[confidence interval (CI) -6.98, -3.82] and PSP 3.2 [CI 2.09, 4.32] (P<0.00001). Improvement in 
PANSS positive, PANSS negative subscales and response rate were significant (P<0.00001). 
Brexpiprazole led to reduced treatment discontinuation due to adverse effects (risk ratio (RR) 0.58), 
however an increased risk of akathisia was observed (RR= 1.31) especially at higher doses but did not 
reach statistical significance. In summary, brexpiprazole improved significantly the symptoms of 
schizophrenia and is well-tolerated, while long-term research is still required to establish its role, 
particularly in patients with co-morbidities. These findings will guide clinical teams in supporting 
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Schizophrenia is a chronic psychiatric disorder that affects 21 
million people worldwide, making one of the leading causes of 
disability (Cooper et al., 2020), where patients’ perception and 
behaviors are significantly altered with diagnosis confirmed 
after full psychiatric assessment (Antoun Reyad and Mishriky, 
2019), In England, the annual incidence of psychotic disorders 
is 32 cases per 100,000 people, 15 of them schizophrenia 
(Kirkbride et al., 2012). Schizophrenia can be idiopathic or 
secondary due to another medical condition or misuse of 
recreational substances (Taj et al., 2008). The aetiology of 
schizophrenia is not fully understood with genetic and 
environmental factors involved (Andreasen, 1999) while 
81.9% of patients suffer a relapse within 5 years of recovery 
(Robinson et al., 1999). Its pathophysiology involves central 
dopamine pathways such as the mesolimbic pathway 
(responsible for emotions, motivation and reward) 
(McCutcheon et al., 2019). A variety of antipsychotics are 
available with choice based on cost, side effect profile and 
patient parameters (Tavcar et al., 2000).  
 
Efficacy of antipsychotic treatment is often measured by 
psychiatric scales such as the Positive and Negative Syndrome 
Scale (PANSS), Clinical Global Impression (CGI) and Brief 
Psychiatric Rating Scale (BPRS). The BPRS is an 18-item 
scoring checklist that evaluate clinical changes and takes into 
account clinical observation as well as the patients’ perception, 
while CGI is based on clinicians’ observations with symptoms 
rated on a scale of 1 to 7 (1= healthy, 7= severely ill). PANSS 
30 items coverspositive, negative and general psychopathology 
symptoms similarly rated on a scale of 1-7 (Mortimer, 2007).  
 
There are two main groups of antipsychotics, typical (first 
generation antipsychotics (FGA)) and atypical (second 
generation). FGA are dopamine (D2) receptors antagonists and 
could also block histamine, muscarinic and alpha-1 receptors 
(Ayano, 2016). Second generation antipsychotics (SGA) are 
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serotonin-dopamine antagonists (Abi-Dargham and Laruelle, 
2005). This 5HT-2A antagonism can increase dopaminergic 
neurotransmission in the nigrostriatal pathway, which reduces 
the risk of extrapyramidal symptoms associated with 
antipsychotic use such as akathisia and tardive dyskinesia 
(Correll et al., 2004) however, SGA are associated with weight 
gain, hyperprolactinemia and glucose intolerance (Ndukwe 
and Nishtala, 2017; Sapra et al., 2016) 
 
Brexpiprazole (Rxulti®, Rexulti®) is a new 2nd generation 
antipsychotic drug for the treatment of schizophrenia and as an 
adjunct in major depressive disorder (Corponi et al., 2019). It 
is a serotonin-dopamine activity modulator and acts as a partial 
agonist of dopamine D2, D3 and 5HT1A receptors, similar to 
cariprazine, and as an antagonist of 5HT2A, 5HT2B, 5HT7 
and adrenergic receptors (Ward and Citrome, 2019) As a 
partial D2 agonist, it is effective in balancing dopamine levels 
in the mesolimbic pathway where hyperactivation leads to 
positive symptoms and the mesocortical pathway where 
hypoactivation leads to negative symptoms (Lieberman, 2004). 
Brexpiprazole also induces neurite outgrowth (Ishima et al., 
2015) and compared to aripiprazole, brexpiprazole has lower 
D2 intrinsic activity with a more potent 5-HT2A antagonism 
(Fornaro et al., 2019). Brexpiprazole is primarily metabolized 
by CYP3A4 and CYP2D6 (Chen et al., 2019) with atarget 
dose of 2-4 mg/day in schizophrenia with dose adjustments 
considered in hepatic or renal dysfunction (Parikh et al., 2017) 
 
Due to its promising mechanism of action, this systematic 
review/meta-analysis was conducted to investigate the efficacy 
and tolerability of brexpiprazole (2-5mg) compared to placebo 
in adult patients (≥ 18 years) suffering from schizophrenia 






The study population included adult patients (18 – 65 years 
old) taking part in RCT’s assigned to either brexpiprazole 2-5 
mg/day, or placebo for the management of acute 
schizophrenia. A literature search was performed using the 
search terms brexpiprazole (OPC-34712), acute schizophrenia 
and placebo in online databases including PubMed, Google 
Scholar, Cochrane Library and Clinicaltrials.gov. Titles were 
screened for relevance, narrowed down using filters for 
‘clinical trials’ and duplicates were removed. The following 
exclusion criteria were applied: studies not in English, 
conducted on children, reviews, incomplete/unpublished data, 
chronic schizophrenia, other psychiatric conditions, 
brexpiprazole doses outside (2-5mg) range. Published phase II 
and III RCTs that investigate the tolerability or efficacy of 
brexpiprazole were included (Table 1).  All RCT’s were 




Data was extracted for primary efficacy outcomes including 
Positive and Negative Syndrome Scales (PANSS), PANSS 
Negative and Positive scores, Clinical Global Impressions-
Severity of Illness Score (CGI-S), Personal and Social 
Performance Scale (PSP) and PANSS Excited Component 
(PEC) (Depp et al., 2010; Mortimer, 2007) with mean changes 
from baseline recorded. PSP takes into account social 
activities, personal relationships, self-care and disturbing 
behaviours (Juckel, 2014). The Response Rate >30% was also 
determined, while safety outcomes included adverse effects 
and discontinuation due to adverse effects. 
 
Statistical Methods  
 
Efficacy and safety outcomes data were added to Review 
Manager (RevMan) (The Cochrane Collaboration, 2014a) 
version 5.3 along with the Cochrane Collaboration tool for 
assessing the risk of bias and to provide statistical values such 
as Chi2, I2, Z-values, P-values, risk ratios (RR) and confidence 
intervals (CI) (Charrois, 2015). Risk of bias was conducted to 
detect selection bias based on randomisation and allocation 
concealment, performance, detection, attrition and reporting 
bias (The Cochrane Collaboration, 2014b). Heterogeneity was 
demonstrated using I2(Higgins et al., 2019), >50% suggests 
heterogeneity and<25% mild heterogeneity (Turlik, 2010), p-
value <0.05 is significant (Ghasemi and Zahediasl, 2012). Risk 
Ratios were used to assess the level of risk associated with an 
intervention (Andrade, 2015). 
 
The inverse variance method was used to calculate the mean 
differences (MD) for continuous outcomes (PANSS, PANSS 
Negative and Positive scores, PANSS excited Component 
score, PSP) and Mantel-Haenszel method to calculate the RR 
for dichotomous outcomes (response rate, risk of 
discontinuation due to adverse effects and common side 




Search Results and Included Studies 
 
Following the database search (PubMed, Google Scholar, 
ClinicalTrials.gov and Cochrane Central Register of 
Controlled), trials were assessed and the process, with reasons 
for exclusion highlighted in the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) chart 
(Figure 1). 5 relevant RCTs met the inclusion criteria (Table 1) 
(Correll et al., 2015; Ishigooka et al., 2018; Kane et al., 2015; 
Lundbeck, 2017; Otsuka Pharmaceutical Development & 
Commercialization., 2015). All studies used were RCTs 
comparing brexpiprazole (dose ranged from 2-5mg/day) and 
placebo in adults with acute Schizophrenia. 
 
Risks of performance and detection bias were low due to all 
trials being randomised, double-blind and placebo controlled 
(Figure 2). Results were collected without investigators being 
aware of the intervention used and the outcome data were 
objective. The risks of selection and attrition bias were unclear 
due to lack of description of the methods used for allocation 
and concealment. 
 
Efficacy of Brexpiprazole compared to Placebo in the 
management of Schizophrenia 
 
5 RCTs for brexpiprazole role in schizophrenia management 
were included, where brexpiprazole was compared with 
placebo with a total of 1272 patients treated with brexpiprazole 
compared to 723 patients who received placebo. All the trials 
assessed PANSS, PANSS positive, PANSS negative (Figure 
3). 
Although individual results varied, most outcomes showed 
homogeneity. The mean change from baseline in PANSS total 
score MD = -5.4 with 95% CI [-6.98, -3.82] showed 
brexpiprazole was favorable compared to placebo (p<0.00001) 
with low heterogeneity between studies (I2 = 0%) (Figure 3). 
Similarly, PANSS positive MD was significantly greater for 
brexpiprazole -1.22 [CI -1.74, -0.70] (p<0.00001) with mild 
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heterogeneity (I233%). PANSS negative subscale and PANSS 
Excited Component scores also showed brexpiprazole 
superiority in the management of schizophrenia MD -1.25 (P 
<0.00001) and -0.92 (P <0.0001) respectively (Figure 3).These 
results were further confirmed by changes in PSP scores with 
an improvement 3.2, CI [2.09, 4.32] and response rate >30% 
showed that brexpiprazole had a statistically significant higher 
response rate with moderate heterogeneity (Figure 3).  
 
Tolerability and Safety of Brexpiprazole compared to 
Placebo in the management of Schizophrenia  
 
The overall RR for trial discontinuation due to adverse effects 
was higher in the placebo group showing brexpiprazole to be 
more favourable (RR= 0.58, p<0.0001) (Figure 4) with some 
variation among the studies. Brexpiprazole was associated 
with a higher risk of akathisia (RR=1.31) (P = 0.1); I2 = 45% - 
moderate heterogeneity and higher doses showed further 
increase in akathisia incidence. Brexpiprazole was also 
associated with nausea and a slight increase in cholesterol but 




Brexpiprazole is a new antipsychotic drug that has been 
licensed for treatment of schizophrenia by the FDA but is still 
waiting to be licensed in the UK. It is structurally similar to 
aripiprazole which is currently used for schizophrenia and 
management of manic episodes (Consilient Health Ltd, 2019). 
Brexpiprazole is thought to have less activity at D2 receptors 
and stronger activity at 5HT2a receptors compared to 
aripiprazole, which could improve the adverse effect profile 
and schizophrenia negative symptoms (Das et al., 2016).  
 
This systematic review investigated the safety and efficacy of 
brexpiprazole for the management of schizophrenia compared 
to placebo using the available clinical trials. Our results 
showed that brexpiprazole improved psychiatric scales used 
for measuring symptom severity in patients with psychosis 
such as PANSS total and its subscales (MD for PANSS (-5.4), 
PANSS positive subscale (-1.22)) (Figure 3). An improvement 
in PANSS, PSP and CGI was also demonstrated (Antoun 
Reyad et al., 2020) and (Kishi et al., 2018) who showed 
brexpiprazole superiority over placebo, however, the (Otsuka 
Pharmaceutical Development & Commercialization., 2015) 
trial found no significant improvement in PANSS scores; this 
could be due to a lack of assay sensitivity in this particular trial 
as the active comparator also showed no improvement in 
PANSS (Kishi et al., 2018).  
 
As far as we are aware, these results update and are consistent 
with previous meta-analysis that showed brexpiprazole 
efficacy such as (Citrome, 2015) and (Antoun Reyad et al., 
2020; Kishi et al., 2018).Our results confirm its superiority in 
management of schizophrenia over placebo (Figure 3) and are 
in agreement with a meta-analysis (Kishi et al., 2018), 
however this meta-analysis did not include some of the recent 
trials included in our meta-analysis. Brexpiprazole is 
considered to have a favorable side effect profile, mainly due 
to its high affinity for 5HT1A and 5HT2A receptors with 
partial D2-agonist activity (Frampton, 2019). In terms of 
safety, brexpiprazole was associated with increased risk of 
headache (p= 0.74), nausea (p= 0.06), anxiety (p= 0.66), 
insomnia (p= 0.31) and akathisia (p=0.1) (Figure 4) but did not 
reach statistical significance. A trend in changes in cholesterol 
levels were detected but these results were not statistically 
significant (p=0.11); more studies would be required to clarify 
the effect of brexpiprazole on cholesterol level as only two 
trials contained data regarding this side effect. Higher doses of 
brexpiprazole had similar efficacy and were observed to have 
increased incidences of akathisia, in particular Otsuka 5mg 
(RR=3.58) and Correll 4mg (RR=3.32) consistent with 
findings by (Antoun Reyad et al., 2020) and (Kishi et al., 
2018). This meta-analysis focused on patients suffering from 
acute schizophrenia whereas (Antoun Reyad et al., 2020) 
looked at acute psychiatric disorders and included trials in 
patients with major depressive disorder and trials comparing 
brexpiprazole with active comparators (quetiapine and 
aripiprazole). There are some limitations such as the lack of an 
active comparator in 3 trials, if included, this could determine 
the safety and efficacy of brexpiprazole compared to the 
currently available antipsychotics and establish its cost-
effectiveness. Adults with insufficient outcomes on 
aripiprazole or bupropion may benefit from switching to 
brexpiprazole (Aladeen et al., 2018). In elderly patients, 
adjunctive brexpiprazole was generally well tolerated with 
improvements in depressive symptoms and social functioning 
(Lepola et al., 2018). Currently, brexpiprazole is under 
investigation for management of other psychiatric conditions 
such as bipolar disorders, borderline personality, agitation in 
AD and Post Traumatic Stress Disorder (PTSD).  
 
This review shows that brexpiprazole is well tolerated and 
significantly improves schizophrenia; however, the results 
need to be interpreted with caution as the treatment length was 
short, with several doses of brexpiprazole used with different 
efficacy and side effect profiles. Therefore, further research 
using different doses over longer periods is recommended for a 
more comprehensive understanding of the safety and efficacy 
of brexpiprazolein the management of chronic schizophrenia, 
especially for patients who have inadequately controlled 
schizophrenia/ require titration to higher doses. There is also 
the implication of co-morbidities and polypharmacy that was 





Figure 1 Flowchart summarizing the studies selection process 
 
 









Figure 3 Efficacy of Brexpiprazole compared with placebo in the management 
of schizophrenia determined by the changes from baseline for (A) Positive and 
Negative Syndrome Scale (PANSS) total score; (B) PANSS positive; (C) 
PANSS negative; (D) PANSS excited component score; (E) Personal and 




Figure 4 Tolerability and Safety of Brexpiprazole compared to Placebo (A) 
Discontinuation from Trials due to Adverse Events; (B) Side Effect-Akathisia; 
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